GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (NAS:GMAB) » Definitions » EBITDA Margin %

GMAB (Genmab AS) EBITDA Margin % : 33.38% (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Genmab AS EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Genmab AS's EBITDA for the three months ended in Sep. 2024 was $275 Mil. Genmab AS's Revenue for the three months ended in Sep. 2024 was $825 Mil. Therefore, Genmab AS's EBITDA margin for the quarter that ended in Sep. 2024 was 33.38%.


Genmab AS EBITDA Margin % Historical Data

The historical data trend for Genmab AS's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS EBITDA Margin % Chart

Genmab AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 56.00 61.05 49.65 50.52 36.17

Genmab AS Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 58.66 21.92 41.59 39.73 33.38

Competitive Comparison of Genmab AS's EBITDA Margin %

For the Biotechnology subindustry, Genmab AS's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab AS's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Genmab AS's EBITDA Margin % falls into.



Genmab AS EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Genmab AS's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=871.862/2410.312
=36.17 %

Genmab AS's EBITDA Margin % for the quarter that ended in Sep. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=275.231/824.65
=33.38 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genmab AS  (NAS:GMAB) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Genmab AS EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Genmab AS's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab AS Business Description

Address
Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.